ORIC Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Our Story ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
ORIC Pharmaceuticals has raised $110M across 2 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Jun 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ORIC Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2023.
ORIC Pharmaceuticals Funding Rounds
ORIC Pharmaceuticals raised $25.0M in an undisclosed round announced in Dec 2022.
6 months later, an undisclosed round of $85.0M was announced in Jun 2023.
ORIC Pharmaceuticals Founders and Leadership Team
Contact details for the ORIC Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →ORIC Pharmaceuticals Funding Compared to Other Biotechnology Startups
ORIC Pharmaceuticals' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ORIC Pharmaceuticals in Biotechnology and South San Francisco
Companies Similar to ORIC Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
ORIC Pharmaceuticals Funding FAQs
What does ORIC Pharmaceuticals do?
Our Story ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
How much funding has ORIC Pharmaceuticals raised?
ORIC Pharmaceuticals has raised $110M across 2 rounds on record. The most recent is an undisclosed round of $85.0M announced in Jun 2023.
When did ORIC Pharmaceuticals last raise funding?
ORIC Pharmaceuticals' most recent funding round on record is an undisclosed round of $85.0M, announced in Jun 2023.
Who founded ORIC Pharmaceuticals?
FundedIQ lists Christian Kuhlen (Founder) at ORIC Pharmaceuticals.
Who is the CEO of ORIC Pharmaceuticals?
Jacob Chacko is listed as CEO at ORIC Pharmaceuticals.
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals is based in South San Francisco, California, United States.
How many employees does ORIC Pharmaceuticals have?
ORIC Pharmaceuticals is in the 101-250 employee band.
How does ORIC Pharmaceuticals' funding compare to other Biotechnology startups?
ORIC Pharmaceuticals' latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ORIC Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ORIC Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.